Stock Report: Myriad Genetics Inc. (MYGN) Report Updated: May 20, 2013 | Print This Page

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Its molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy to ensure optimal dosing and reduced drug toxicity. The company offers various molecular diagnostic tests that include BRACAnalysis predictive medicine test for hereditary breast and ovarian cancer; COLARIS medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; and MELARIS medicine test for hereditary melanoma. It also provides OnDose, a personalized medicine test that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. In addition, the company, through its subsidiary, Myriad RBM, Inc., offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.